Skip to content

Midline Catheter Versus Long Peripheral Intravenous Catheter in Hospitalized Adult Patients

Midline Catheter Versus Long Peripheral Intravenous Catheter in Hospitalized Adult Patients: Randomized Clinical Trial With Economic Analysis From the Perspective of the Public Health System.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05884294
Enrollment
102
Registered
2023-06-01
Start date
2024-01-02
Completion date
2025-03-01
Last updated
2025-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vascular Access Devices

Keywords

vascular access device, midline catheter, long Peripheral Intravenous Catheter

Brief summary

This research seeks to compare two types of vascular access (catheters that are inserted into the vein) for patient treatment during hospitalization. This research will evaluate how long each catheter lasts before presenting problems that may lead to its removal from the vein (the most common are swelling on the site of the catheter, clogging of the catheter, infections, or other less common problems. Each patient will be randomly selected to receive either catheter. In this study, we will also estimate how much each patient will spend if any of the problems mentioned occur.

Detailed description

This randomized, parallel, open, controlled, single-center clinical trial is blind to outcome analysis. The use of midline catheter will be compared, regarding duration of use without complications, to the use of long peripheral intravenous catheter during continuous our intermittent intravenous therapy in adult clinical patients who have been hospitalized for up to 30 days. The intervention group will consist of hospitalized adult clinical patients who were identified with difficult intravenous access (DIVA) and who received medical indication of continuous or intermittent intravenous therapy for more than five and a maximum of 30 days of treatment. These patients will receive PowerGlide ProTM Midline catheter. The control group will consist of patients with the same profile described as the intervention group and will receive the insertion of a long peripheral venous catheter Introcan Safety Deep Access. At the end of the study, an economic analysis will be carried out from the perspective of the public health system if the intervention group shows favorable results.

Interventions

DEVICEPowerGlide Pro Midline catheter.

The Intervention Group will be represented by hospitalized adult clinical patients who have been identified with difficult intravenous access. These patients will receive an ultrasound-guided insertion of the PowerGlide ProTM Midline 20G (10 cm).

Sponsors

Hospital de Clinicas de Porto Alegre
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Masking description

This study will be blind to statistical analysis.

Intervention model description

randomized, parallel, open, controlled, and single-center clinical trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients hospitalized in a clinical ward unit; * indicated for continuous or intermittent intravenous therapy more than five days; * identified with difficult intravenous access.

Design outcomes

Primary

MeasureTime frameDescription
Lenght of time of vascular access without isolated or combined complications.up to 30 days, end of therapy or withdrawal due to any complicationTime in days.

Secondary

MeasureTime frameDescription
First-attempt puncture successup to 30 days or end of therapysuccess in the first venipuncture, number venipuncture.

Other

MeasureTime frameDescription
Economic analysis30 days or end of therapy.micro-costing

Countries

Brazil

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026